Steven Cohen’s Xeris Biopharma Holdings XERS Stock Holding History

Steven Cohen’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-608,080	Closed	-$4.77M	–	4604
2025 Q4	$4.77M	Buy	+608,080	New	+$4.79M	0.01%	1881
2025 Q3	–	Sell	-45,100	Closed	-$211K	–	2744
2025 Q2	$211K	Sell	45,100 -43,273	-49%	-$198K	﹤0.01%	1974
2025 Q1	$485K	Buy	+88,373	New	+$357K	﹤0.01%	1638
2023 Q4	–	Sell	-655,000	Closed	-$1.22M	–	2922
2023 Q3	$1.22M	Buy	+655,000	New	+$1.5M	﹤0.01%	1269
2023 Q1	–	Sell	-60,000	Closed	-$79.8K	–	2576
2022 Q4	$79.8K	Buy	+60,000	New	+$84.7K	﹤0.01%	1317
2020 Q3	–	Sell	-232,410	Closed	-$618K	–	1122
2020 Q2	$618K	Buy	+232,410	New	+$809K	﹤0.01%	701
2018 Q3	–	Sell	-5,000	Closed	-$95K	–	1243
2018 Q2	$95K	Buy	+5,000	New	+$97.2K	﹤0.01%	933

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steven Cohen's XERS Position: Q1 2026 in Review

Steven Cohen sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 608,080 shares — an estimated $4.77M sold.

Steven Cohen first reported a position in XERS in Q2 2018 and held it in 7 quarters. The position peaked at $4.77M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Steven Cohen reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 608,080 Xeris Biopharma Holdings shares in Q1 2026, an estimated $4.77M.
Steven Cohen first reported a position in Xeris Biopharma Holdings in Q2 2018 and held it in 7 quarters.
Steven Cohen's Xeris Biopharma Holdings position peaked at $4.77M in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.